| 301 | ANIKAnika Therapeutics, Inc. |
112,8 mln USD |
-9,6% |
2025 |
| 302 | URGNUroGen Pharma Ltd. |
109,8 mln USD |
-139,8% |
2025 |
| 303 | IPSCCentury Therapeutics, Inc. |
109,2 mln USD |
-8,8% |
2025 |
| 304 | MDXHMDxHealth SA |
107,9 mln USD |
-31,1% |
2025 |
| 305 | TBPHTheravance Biopharma, Inc. |
107,5 mln USD |
98,5% |
2025 |
| 306 | ZVRAZevra Therapeutics, Inc. |
106,5 mln USD |
78,2% |
2025 |
| 307 | ZYMEZymeworks Inc. |
106 mln USD |
-76,6% |
2025 |
| 308 | SMTISanara MedTech Inc. |
103,1 mln USD |
-36,4% |
2025 |
| 309 | STROSutro Biopharma, Inc. |
102,5 mln USD |
-186,5% |
2025 |
| 310 | BBNXBeta Bionics, Inc. |
100,3 mln USD |
-73,0% |
2025 |
| 311 | NPCENeuroPace Inc |
100 mln USD |
-21,5% |
2025 |
| 312 | BFLYButterfly Network, Inc. |
97,6 mln USD |
-79,0% |
2025 |
| 313 | BLFSBiolife Solutions Inc |
96,2 mln USD |
-4,8% |
2025 |
| 314 | ISPRIspire Technology Inc. |
96 mln USD |
-34,6% |
2026 |
| 315 | KMTSKestra Medical Technologies, Ltd. |
95,1 mln USD |
-138,4% |
2026 |
| 316 | SIGASiga Technologies Inc |
94,6 mln USD |
24,6% |
2025 |
| 317 | LUNGPulmonx Corp |
90,5 mln USD |
-59,7% |
2025 |
| 318 | CBLLCeribell, Inc. |
89,1 mln USD |
-60,0% |
2025 |
| 319 | BDSXBiodesix Inc |
88,5 mln USD |
-39,8% |
2025 |
| 320 | CYTKCytokinetics Inc |
88 mln USD |
-891,6% |
2025 |
| 321 | DCTHDelcath Systems, Inc. |
85,2 mln USD |
3,2% |
2025 |
| 322 | FDMT4D Molecular Therapeutics, Inc. |
85,2 mln USD |
-164,4% |
2025 |
| 323 | SPRYARS Pharmaceuticals, Inc. |
84,3 mln USD |
-203,3% |
2025 |
| 324 | NRIXNurix Therapeutics, Inc. |
84 mln USD |
-314,9% |
2025 |
| 325 | IRMDIradimed Corp |
83,8 mln USD |
26,8% |
2025 |
| 326 | ARCTArcturus Therapeutics Holdings Inc. |
82 mln USD |
-80,2% |
2025 |
| 327 | FTLFFitlife Brands, Inc. |
81,5 mln USD |
7,8% |
2025 |
| 328 | MGTXMeiraGTx Holdings plc |
81,4 mln USD |
-140,3% |
2025 |
| 329 | ADCTADC Therapeutics SA |
81,4 mln USD |
-175,3% |
2025 |
| 330 | ETONEton Pharmaceuticals, Inc. |
80 mln USD |
-5,8% |
2025 |
| 331 | PDEXPro Dex Inc |
77,5 mln USD |
17,6% |
2026 |
| 332 | SGHTSight Sciences, Inc. |
77,4 mln USD |
-49,7% |
2025 |
| 333 | BNRBurning Rock Biotech Ltd |
77,2 mln USD |
-10,3% |
2025 |
| 334 | CTMXCytomX Therapeutics, Inc. |
76,2 mln USD |
-22,8% |
2025 |
| 335 | AUTLAutolus Therapeutics plc |
75,4 mln USD |
-381,4% |
2025 |
| 336 | ABCLAbCellera Biologics Inc. |
75,1 mln USD |
-194,9% |
2025 |
| 337 | RXRXRecursion Pharmaceuticals, Inc. |
74,7 mln USD |
-863,4% |
2025 |
| 338 | ELMDElectromed, Inc. |
73,8 mln USD |
15,3% |
2026 |
| 339 | CLLSCellectis S.A. |
72,9 mln USD |
-92,7% |
2025 |
| 340 | CGENCompugen Ltd |
72,8 mln USD |
48,6% |
2025 |
| 341 | BCYCBicycle Therapeutics PLC |
72,6 mln USD |
-301,7% |
2025 |
| 342 | ASMBAssembly Biosciences, Inc. |
72,3 mln USD |
-8,5% |
2025 |
| 343 | VRDNViridian Therapeutics, Inc. |
70,8 mln USD |
-483,6% |
2025 |
| 344 | FOCLEdap Tms SA |
70,5 mln USD |
-41,5% |
2025 |
| 345 | BDTXBlack Diamond Therapeutics, Inc. |
70 mln USD |
32,0% |
2025 |
| 346 | PSNLPersonalis, Inc. |
69,6 mln USD |
-116,7% |
2025 |
| 347 | VIRVir Biotechnology, Inc. |
68,6 mln USD |
-638,9% |
2025 |
| 348 | NTLAIntellia Therapeutics, Inc. |
67,7 mln USD |
-609,9% |
2025 |
| 349 | KURAKura Oncology, Inc. |
67,5 mln USD |
-412,9% |
2025 |
| 350 | SPROSpero Therapeutics, Inc. |
66,8 mln USD |
12,8% |
2025 |